Blood cancer Archives

News and Trends 11 Dec 2017

New Antibody-Drug Conjugate Offers Hope to Hard-to-Treat Cancer Patients

ADC Therapeutics has tested its antibody-drug conjugate technology in drug-resistant cancers, yielding encouraging results. Swiss biotech ADC Therapeutics is one of our top biotechs of the year after it brought in a massive $200M (€170M) fundraising round. The company develops antibody-drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Results from two Phase I studies […]

December 11, 2017 - 3 minutesmins - By Alex Dale

News and Trends 4 Dec 2017

Dutch Bone Marrow Transplant for Blood Cancer could get rid of Donor Matching

Kiadis Pharma starts Phase III trials with ATIR101, a therapy that could make half-matched donors suitable for bone marrow transplant to treat blood cancer. From its Amsterdam headquarters, Kiadis Pharma is developing a technology that could solve one of the biggest problems of bone marrow transplantation: finding a donor match. Currently, a bone marrow transplant is […]

December 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 17 Nov 2017

Welcome to the Blockbuster Club, Genmab!

Genmab has achieved $1B sales in the US of its blood cancer drug, Darzalex, setting a great example for other European biotechs to follow. Genmab has officially joined the elite of the biotech world by achieving $1B (€850M) in sales of its drug for multiple myeloma, Darzalex. The biotech will now receive milestone payments of $50M (€42M) […]

November 17, 2017 - 3 minutesmins - By Alex Dale

News and Trends 14 Nov 2017

This British Biotech Could Treat T-Cell Lymphoma without Leaving the Body Unprotected

Autolus has revealed a new strategy to treat T-cell lymphoma without harming healthy, protective T cells. The therapy is expected to start human tests soon. T-cell lymphoma is a form of cancer that affects the cells responsible for protecting our body against infections. Unlike it’s done with cancer types that affect other blood cells, it’s […]

November 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Oct 2017

The FDA Approves a Second CAR-T Therapy, Cheaper than Novartis’

Gilead’s CAR-T cell therapy Yescarta has been approved by the FDA, making it the first competitor for Novartis’ CAR-T Kymriah. Yescarta (axicabtagene ciloleucel, or axi-cel for short) has become the second CAR-T therapy to be approved in the US. The FDA has authorized its use to treat aggressive B-cell non-Hodgkin lymphoma in patients for whom at least two […]

October 19, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 21 Jul 2017

Roche Abandons Spanish Cancer Epigenetics Drug

Roche has decided to terminate its license agreement with Spanish biotech Oryzon Genomics after rearranging its portfolio priorities. Oryzon Genomics, a biotech based in Barcelona working on epigenetics, was notified yesterday by Roche about the discontinuation of their deal concerning the biotech’s lead candidate, ORY-1001. Roche announced the decision was not based on clinical data, […]

July 21, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 28 Jun 2017

UPDATE: The First Off-the-Shelf CAR-T Cancer Therapy has Entered the Clinic

Update (28/06/2017): Cellectis has announced the first administration of UCART123 in its Phase I trial in Acute Myeloid Leukemia. Update (07/02/2017): the FDA has granted Cellectis IND approval to start clinical trials with UCART123. Original publication 04/01/2017 Cellectis is preparing to start the first clinical trial ever using an allogeneic CAR-T therapy that could reduce […]

June 28, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Interview 22 May 2017

Meet the New CEO of the Dutch Biotech Making a Cure for Blood Cancer

Arthur Lahr, CEO of Kiadis Pharma, explains the promising cell therapy the company is developing and discusses how the dutch biotech ecosystem has evolved. Arthur Lahr has been part of the Dutch biotech scene for over 15 years now. The former Chief Strategy Officer of Crucell, which was sold to J&J in 2011, is now […]

May 22, 2017 - 7 minutesmins - By Clara Rodríguez Fernández

News and Trends 13 Apr 2017

Next-Gen Cancer Antibody Technology from Germany enters the Clinic

Apogenix’ partner AbbVie has started the first clinical trial for an immuno-oncology candidate with the potential to outperform antibody therapy. The German biotech Apogenix has announced that its partner AbbVie has initiated a Phase I trial testing its next-generation immuno-oncology technology in patients suffering from solid tumors, non-Hodgkin’s lymphoma (NHL) and acute myeloid leukemia (AML). The candidate […]

April 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Apr 2017

UPDATE: Norwegian Stock Exchange hits Record Biotech IPO

UPDATE (06/04/2017): BerGenBio has raised €43.55M, successfully beating a biotech record on the Norwegian stock exchange and setting its market cap at €135M. UPDATE (28/03/2017): BerGenBio has announced that the IPO could run up to €44M on Oslo Børs. It could become the Norway stock exchange’s biggest IPO in biotech, and indeed €44M would make it […]

April 6, 2017 - 3 minutesmins - By Melanie De Almeida

Interview 23 Mar 2017

Meet the CEO of this Intrepid Spanish Biotech exploring Epigenetics

Located right here in Barcelona, Oryzon is one of the world’s few epigenetics biotechs. I sat down with CEO Carlos Buesa to talk about its approach. Since its foundation in 2000, Oryzon has gone on to become the leader in epigenetic medicine and focuses on oncology. Most recently, the company announced the success of its lead […]

March 23, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 1 Mar 2017

Swedish Oncology Biotech makes a Large IPO for its Peptides

The Swedish company Oncopeptides raised €68M with its IPO on Nasdaq Stockholm, which will allow the company to push their compound into phase III trials. Oncopeptides was founded in 2000 and is focused on the development of its lead compound Ygalo. After the company started a Phase II trial in patients with late stage relapsed and refractory multiple […]

March 1, 2017 - 3 minutesmins - By Melanie De Almeida

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Blood cancer

New Antibody-Drug Conjugate Offers Hope to Hard-to-Treat Cancer Patients

Dutch Bone Marrow Transplant for Blood Cancer could get rid of Donor Matching

Welcome to the Blockbuster Club, Genmab!

This British Biotech Could Treat T-Cell Lymphoma without Leaving the Body Unprotected

The FDA Approves a Second CAR-T Therapy, Cheaper than Novartis’

Roche Abandons Spanish Cancer Epigenetics Drug

UPDATE: The First Off-the-Shelf CAR-T Cancer Therapy has Entered the Clinic

Meet the New CEO of the Dutch Biotech Making a Cure for Blood Cancer

Next-Gen Cancer Antibody Technology from Germany enters the Clinic

UPDATE: Norwegian Stock Exchange hits Record Biotech IPO

Meet the CEO of this Intrepid Spanish Biotech exploring Epigenetics

Swedish Oncology Biotech makes a Large IPO for its Peptides

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!